



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**26 October 2017**

---

## **Bionomics & MSD to Host 5<sup>th</sup> Annual Neuroscience Symposium**

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today will co-host its annual neuroscience symposium with MSD at 9:15 a.m. ACDT in Adelaide, Australia.

Some of the key presentations at the symposium will be:

- **Professor Steve Williams**, IoPPN Kings College London & Maudsley Hospital on MR Neuroimaging to Facilitate the Drug R&D Process - from Mouse to Man
- **Professor Ole Isacson**, Professor of Neurology & Neuroscience, Harvard Medical School on Novel Concepts from Human Cell Biology and Genetics for Neurodegenerative Disease Treatments
- **Dr. Richard Hargreaves**, Corporate Vice President Neuroscience & Imaging, Celgene on Seeing the Problems and Devising Solutions for Neurodegenerative Disease

A live audio webcast can be accessed on the Bionomics website, [www.bionomics.com.au](http://www.bionomics.com.au) or by copying the following to your web browser: <http://bionomics.streaming.net.au/>. An archived replay of the webcast will be available for 30 days after the live event concludes.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

**Australia**  
Monsoon Communications  
Rudi Michelson  
+613 9620 3333  
[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**US**  
Stern Investor Relations  
Beth DelGiaccio  
+1 212 362 1200  
[beth@sternir.com](mailto:beth@sternir.com)

### **About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

[www.bionomics.com.au](http://www.bionomics.com.au)

**Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.